Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
KesimptaⓇ launch momentum continues - demand expected to
double in H2 vs. H1
Launch progress in US
NBRX +71%, 2nd highest NBRx share
ahead of AubagioⓇ and TecfideraⓇ
USD 66m Q2 sales, +58% QoQ1
KesimptaⓇ NBRX²
New-to-brand prescriptions
+71%
>5k patients treated, 2x vs. Q1
51% of patients naive or first switch
1,832
<5 days to 1st dose in 80% of patients
1,074
>500 new prescribers vs. Q1
Q1 2021
Q2 2021
Foundation for continued growth
Dynamic market recovery
as vaccination campaign progresses
Expansion of B-cell market as shift
to high-efficacy therapies continues
Differentiation based on unique
PIRA and IgG data
Growing awareness and familiarity with
KesimptaⓇ to drive broader adoption
Launch in 13 markets expected
by year end 2021
PIRA - Progression independent of relapses IgG - Immunoglobulin G 1. Excluding 9m adjustment related to faster than expected conversion from free to paid product in prior quarter.
2. Cumulative NBRx for the quarter.
23 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation